However, the results showed limited clinical efficacy in GC patients due to a variety of reasons, including the development of resistance mechanisms, the intrinsic complexity of the MET pathway, and inadequate identification of relevant biomarkers [23]. The gene discussed is MET; the disease is gastric cancer.